Cantor Fitzgerald Comments on Amgen FY2026 Earnings

Amgen Inc. (NASDAQ:AMGN - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Amgen in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst C. Gould forecasts that the medical research company will post earnings of $21.58 per share for the year. Cantor Fitzgerald has a "Neutral" rating and a $305.00 price objective on the stock. The consensus estimate for Amgen's current full-year earnings is $20.62 per share.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.72. The firm had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The company's revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the previous year, the company earned $3.96 EPS.

Several other equities analysts have also issued reports on AMGN. Morgan Stanley reaffirmed an "equal weight" rating on shares of Amgen in a research note on Friday, May 2nd. Johnson Rice set a $294.00 price objective on Amgen in a report on Wednesday, March 5th. Mizuho upped their target price on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research report on Wednesday, May 7th. Bank of America raised their price target on Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a research report on Wednesday, March 5th. Finally, Royal Bank of Canada lowered their target price on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Amgen currently has an average rating of "Hold" and a consensus price target of $309.22.

Amgen Price Performance

NASDAQ AMGN traded up $3.45 on Tuesday, hitting $293.43. 2,441,018 shares of the company were exchanged, compared to its average volume of 2,808,700. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The company has a market cap of $157.78 billion, a P/E ratio of 38.86, a P/E/G ratio of 2.63 and a beta of 0.51. The firm has a 50 day moving average of $281.26 and a two-hundred day moving average of $285.36. Amgen has a 1-year low of $253.30 and a 1-year high of $346.85.

Hedge Funds Weigh In On Amgen

Several hedge funds have recently made changes to their positions in AMGN. Wealth Preservation Advisors LLC bought a new position in shares of Amgen in the first quarter valued at $25,000. First Pacific Financial raised its stake in Amgen by 304.5% in the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company's stock worth $28,000 after purchasing an additional 67 shares in the last quarter. CBIZ Investment Advisory Services LLC increased its holdings in shares of Amgen by 1,214.3% during the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company's stock worth $29,000 after purchasing an additional 85 shares during the period. Centricity Wealth Management LLC acquired a new position in Amgen in the 4th quarter valued at $25,000. Finally, Pinney & Scofield Inc. bought a new stake in shares of Amgen during the 4th quarter valued at $26,000. 76.50% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the business's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the sale, the senior vice president now owns 8,162 shares in the company, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.76% of the stock is owned by corporate insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.